Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18514975 | 0.93 | LMNA (0.40) | LMNAGAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18749008 | 0.90 | MAPT (0.44) | GAAKMT2ASMN1; SMN2MAPTPOLB | |
| SCHEMBL18748831 | 0.90 | SLC22A12 (0.41) | LMNAGAASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL18748815 | 0.89 | MAPT (0.51) | LMNAGAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18749150 | 0.89 | LMNA (0.48) | LMNAGAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18748862 | 0.89 | HPGD (0.38) | LMNAGAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18748866 | 0.88 | LMNA (0.38) | LMNAGAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18748957 | 0.88 | GAA (0.40) | LMNAGAAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL18513867 | 0.87 | MAPT (0.45) | LMNAGAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18749006 | 0.87 | LMNA (0.41) | LMNAGAAKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9907307-B2 | Aromatic compound and uses thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-03-06 | — | — | US | disclosed |
| US-9788547-B2 | Aromatic compound and uses thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-17 | — | — | US | disclosed |
| US-20170105413-A1 | AROMATIC COMPOUND AND USES THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170105416-A1 | AROMATIC COMPOUND AND USES THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170105413-A1 | AROMATIC COMPOUND AND USES THEREOF | TYR, H1-3, H1-0 | LMNA 2808/4885GAA 3081/4885KMT2A 705/4885 |
| US-20170105416-A1 | AROMATIC COMPOUND AND USES THEREOF | TYR, H1-3, H1-10 | LMNA 3163/4885GAA 3763/4885KMT2A 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.